Cefalexin

Quick links to important sections

Cefalexin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefalexin

Property Description
Active ingredient Cefalexin monohydrate
Form Capsule, tablet, oral suspension
Pharmacological class First-generation cephalosporin antibiotic
Common use Resolution of bacterial infections
Origin Semi-synthetic

What Type of Medicine is Cefalexin?

Cefalexin, also known by its synonym Cephalexin, is a semi-synthetic beta-lactam antibiotic that belongs to the first-generation cephalosporin class. It is a prescription drug (Rx) and is fundamentally defined by its active chemical entity, Cefalexin monohydrate. The classification as a cephalosporin sets it apart from other antibiotic classes, yet its shared beta-lactam core links it functionally to penicillins. In clinical practice, Cefalexin serves as a primary oral antimicrobial agent for susceptible bacteria. The drug is commonly known under commercial names such as Keflex and Biocef, though the INN Cefalexin remains the universal standard for the active compound.


Cefalexin’s Physical Form and Composition

The active ingredient, Cefalexin monohydrate, is specifically formulated for effective oral administration. As a single-entity product, it is prepared in several pharmaceutical preparations, primarily solid forms like capsules and compressed tablets, alongside a liquid oral suspension. The availability of the oral suspension is particularly important as it allows for precise dosing and easier consumption for specific patient groups, such as pediatric patients. The composition of these forms consists of the active drug substance and necessary excipient fillers or an aqueous base designed to ensure stability and proper absorption in the body.


What is the General Purpose of Cefalexin?

The general purpose of Cefalexin is the successful resolution of underlying systemic bacterial infections through its bactericidal effect on invading pathogens. This action involves interfering with the synthesis of the bacterial cell wall, a mechanism that actively kills the targeted organisms. The World Health Organization (WHO) includes Cefalexin on its Model List of Essential Medicines, reflecting its role in global health systems. This capability highlights the drug's intended function as a broad-spectrum agent for eliminating bacterial threats in typical use scenarios, such as treating common skin or respiratory bacterial infections.

Regulatory References

  1. NIH Clinical Summary
  2. FDA Drug Label

What side effects are possible with Cefalexin?

Possible Side Effects and Safety Information

The safety profile of Cefalexin is characterized by officially documented adverse reactions classified by frequency and affected body systems, derived from government regulatory labeling. The most frequently reported effects, classified as Common in regulatory documents, typically involve Gastrointestinal Disorders, primarily diarrhoea and nausea.

Adverse Reaction Classifications

Adverse effects listed as Uncommon include reversible increases in liver enzymes and reactions affecting the skin, such as rash, urticaria, and pruritus. Rare adverse reactions span multiple systems and include serious events such as haemolytic anaemia, hepatitis, and pseudomembranous colitis.

Serious Adverse Reactions and Safety Constraints

Official labeling identifies several clinically significant adverse reactions. These include severe hypersensitivity reactions like anaphylaxis and severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Regulatory notes also document the risk of interstitial nephritis and potential neurotoxicity, including seizures, particularly in patients with renal impairment.

There is evidence of partial cross-allergenicity between Cefalexin and penicillins. Additionally, prolonged use carries the documented risk of superinfection from the overgrowth of non-susceptible organisms. Safety constraints also include the potential for laboratory test interference, such as a positive direct Coombs' test.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Cefalexin structures the overdose profile around specific clinical manifestations and mandated emergency actions.

Overdose Scope

Property Official Regulatory Statement
Documented Overdose Presentations Nausea, Vomiting, Diarrhea, Stomach pain, and Chromaturia (pink, red, or dark brown urine).
Physiological Systems Affected Gastrointestinal, Urinary/Renal, and Central Nervous System (CNS).
Population-Specific Notes Increased potential for toxicity, including seizures, is noted in patients with markedly impaired renal function due to drug accumulation.

Emergency Actions and Required Help

Immediate Action Conditions Requiring Emergency Services (911)
Seek immediate medical attention. Seizure, Collapse, Trouble breathing, or Unresponsiveness.

Management is officially defined as symptomatic and supportive treatment, a constraint consistent with the regulatory statement that no specific antidote is known or available. The regulatory basis for this information details events ranging from mild gastrointestinal symptoms to life-threatening CNS effects.

Connection to the overall overdose profile: Regulatory documents define the Cefalexin overdose profile by detailing specific, documented manifestations and linking the most severe outcomes (seizures, collapse) to mandatory, immediate emergency-seeking conditions. The protocol requires urgent attention, particularly because the increased toxicity risk in the renally impaired population necessitates heightened clinical observation.

Therapeutic Uses of Cefalexin

What Cefalexin Treats: Main Uses and Benefits

Cefalexin is an oral antibiotic generally used for the management of infections caused by susceptible bacteria. Its role contributes to easing the overall symptom burden associated with acute and highly uncomfortable episodes across several therapeutic domains. This medication is commonly used across conditions presenting with acute episodes, including infections of the skin and soft tissues, the upper respiratory tract, the middle ear (otitis media), and uncomplicated urinary tract infections (UTIs).

This medication is applied across domains where additional symptomatic support is needed and is relevant for easing symptoms related to inflammatory or irritative states.

“Cefalexin is relevant in contexts involving heightened systemic burden, supporting patients during difficult episodes by easing distress.”

Symptom-Focused Relief

Cefalexin helps address symptom clusters that may become intense or disruptive, such as localized redness and swelling from skin infections, severe sore throat or ear pain, and distressing manifestations like painful or frequent urination. It is associated with improved comfort during periods of heightened symptoms and may assist with supporting functional stability. It is often used during phases when symptoms become more noticeable, in scenarios requiring short-term symptomatic assistance, or when conditions involving localized inflammation are managed.


Quick Fact: Relief for Inflammation and Pain

Cefalexin is commonly used to help with symptoms related to inflammatory or irritative states and is relevant for easing localized discomfort and systemic signs like fever that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview of Cephalexin

Eligibility and Restrictions for Use

Who Can and Cannot Use Cefalexin?

Cefalexin’s eligibility is defined by official regulatory rules, separating established use from restricted or contraindicated populations.

The medicine is contraindicated and must not be used in individuals with a known allergy or hypersensitivity to Cefalexin or any other drug belonging to the cephalosporin class of antibiotics. Contraindications may also apply based on formulation excipients, such as in patients with rare hereditary problems like galactose or fructose intolerance.

Use is established for adults and pediatric patients over 1 year of age under standard labeled conditions. However, the following patient groups require specific caution or restricted use:

  • Renal Impairment: Patients with markedly impaired renal function require cautious use and mandatory dosage adjustment due to altered drug clearance.
  • Prior Allergy History: Caution must be exercised in patients with a history of penicillin hypersensitivity due to the potential for cross-allergy.
  • Pregnancy and Lactation: Use in pregnant patients (FDA Category B) and nursing mothers requires specific caution, as the drug is excreted into breast milk.
  • Comorbidities: Caution is advised for those with a history of gastrointestinal disease, particularly colitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cefalexin, like all medications, may interact with certain other medicines, supplements, or medical tests. Patients should inform their healthcare provider of all products they are taking before starting treatment.

Interacting Product Category Key Effect and Management Note
Metformin (for diabetes) Cefalexin can increase metformin concentrations in the blood by slowing its elimination by the kidneys. This may increase the risk of low blood sugar, and dose adjustments may be necessary.
Probenecid (for gout) Probenecid can inhibit the renal excretion of cefalexin, resulting in higher and prolonged levels of the antibiotic in the bloodstream.
Oral Anticoagulants (e.g., Warfarin) Cefalexin may enhance the effects of anticoagulants, increasing the risk of bleeding. Close monitoring of blood clotting parameters, such as the International Normalized Ratio (INR), is typically required.
Live Vaccines (e.g., Oral Typhoid) The antibiotic may reduce the effectiveness of live bacterial vaccines. These combinations are generally restricted.
Zinc-Containing Products Zinc supplements can decrease the absorption of cefalexin from the digestive system, potentially reducing its effectiveness. Administration of cefalexin and zinc-containing products should be separated by at least three hours.
Diuretics (e.g., Furosemide) Caution is advised when used with other drugs that may affect kidney function, particularly in patients with pre-existing renal impairment.

Additionally, cefalexin can cause a false-positive result for glucose in the urine when using certain testing solutions, such as Benedict's or Fehling's solution. It may also cause a positive direct Coombs' test, which could complicate blood cross-matching procedures.

Mechanism of Action

Cefalexin exerts its action by interfering with the structural integrity of susceptible bacteria. The drug functions as an irreversible inhibitor of bacterial Penicillin-Binding Proteins (PBPs), which are transpeptidase enzymes required for the final step of peptidoglycan cross-linking. The molecule achieves this by forming a covalent bond with the active site of the PBP enzyme, thereby halting the construction of the bacterial cell wall.

This structural failure initiates a mechanistic cascade leading to cell rupture. The compromised cell wall cannot withstand the high internal osmotic pressure of the bacterium, causing a rapid influx of water. This pressure imbalance results in cell swelling and lysis, which is the core bactericidal effect. The mechanism is specific to the peptidoglycan pathway, which is absent in human cells. Resistance may constrain this action when bacteria produce beta-lactamase enzymes that degrade the drug's active ring.

Dosage and Administration Information

Official Administration Guidelines

Cefalexin is administered orally in the form of capsules, tablets, or liquid suspension. It may be taken with or without food, as absorption is not appreciably altered, though taking it with food may reduce potential gastrointestinal discomfort.

Dosing and Frequency

Dosage is determined by the patient's age and, where applicable, weight and kidney function. Treatment is typically required for a course of 7 to 14 days, and the medication must be taken for the full duration prescribed, even if symptoms improve early.

Population Usual Dosage and Frequency (Selected Regimens)
Adults (ge 15 years) 250 mg every 6 hours OR 500 mg every 12 hours. Total daily doses range from 1 g to 4 g, divided into multiple doses.
Pediatric (Over 1 year) 25 mg/kg to 50 mg/kg of body weight per day, divided into equal doses. For certain infections (e.g., otitis media), up to 75 mg/kg to 100 mg/kg per day, divided into four doses, may be required.
Renal Impairment Dose adjustment is required for markedly impaired renal function. For example, a maximum daily dose should not exceed 1 g for Creatinine Clearance (CrCl) 30 to 59 mL/min, and 250 mg every 24 hours for CrCl 5 to 14 mL/min (not on dialysis).

Preparation and Handling

  • Tablets/Capsules: Should be swallowed whole with water.
  • Oral Suspension (Liquid): The powder must be properly reconstituted by adding the specified amount of water and shaking thoroughly. The suspension must be shaken well before each subsequent use to ensure the correct dose is measured. The liquid form is typically stored in the refrigerator after mixing and must be discarded after the designated time period, usually 14 days.

Recent Clinical Evidence

Cefalexin: Recent Clinical Evidence

This section provides an overview of the types of research and clinical studies that have been conducted on Cefalexin, focusing on what was measured, the populations observed, and what remains unclear in the evidence. This information is presented for context and does not offer individual medical advice or treatment recommendations.


Evidence for Use in Skin and Soft Tissue Infections (SSTIs)

The research base for Cefalexin’s administration in SSTIs includes short-term Randomized Controlled Trials and comparative studies. Researchers specifically measured outcomes like the rate of clinical outcome measurements (tied to inflammatory states like redness and swelling) and the rate of bacteriological outcome measurements (the observed presence or absence of bacteria). Studies report how symptoms evolved in the observed populations, which included both adults and pediatric patients. Long-term effects are not fully established regarding research exploring patterns related to infection recurrence in non-prophylactic contexts.

Evidence for Use in Uncomplicated Urinary Tract Infections (UTIs)

The research for uncomplicated UTIs involves short-term RCTs and observational studies. These studies monitored outcomes related to physical discomfort, specifically the observed absence or presence of acute manifestations like painful or frequent urination. Research examined the drug’s concentration in the urine, and data show patterns related to bacteriological outcome measurements. Evidence remains limited regarding study outcomes for all types of upper UTIs.

Evidence in Special Populations

Cefalexin was evaluated in specific demographic groups, confirming that the research base includes significant data on pediatric patients. In contexts like Bone and Joint Infections (BJIs), research explored its use in both adults and children as part of step-down protocols (transitioning from intravenous to oral treatment). However, there is limited information for long-term outcomes in older adults or in patients with certain complex or comorbid conditions.

What is Still Uncertain About Cefalexin Research

The evidence quality varies across studies, and there are several areas where certainty remains low. Comparative evidence is lacking with respect to some newer antibiotics now in use. The existing data for certain groups, such as those with unique comorbidities, remain insufficient to draw broad conclusions, and long-term effects are not fully established beyond the acute treatment phase.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Clinical Guideline: Urinary tract infection (UTI) in adults (Supporting UTI evidence)
  2. National Institutes of Health (NIH) Clinical Summary: Cephalexin Overview

Frequently Asked Questions (FAQ)

Common questions about Cefalexin (FAQ)

Q: How quickly does Cefalexin usually start to show an effect?

A: According to official product information and patient counseling guides, patients should typically begin to feel better within the first few days of treatment. Cefalexin is rapidly absorbed, reaching its peak levels in the bloodstream approximately one hour after administration. However, patients are typically advised to complete the full course as prescribed, even if symptoms improve.

Q: Is it common to experience stomach upset or diarrhea when taking Cefalexin?

A: Yes, regulatory documents list diarrhea and nausea (stomach upset) among the most commonly reported adverse reactions. If symptoms are severe or concerning, regulatory guidance advises seeking professional medical evaluation.

Q: What should I do if I miss a dose of Cefalexin?

A: Official labeling emphasizes taking the medicine exactly as directed and completing the full course. Specific instructions for missed doses should be obtained from the prescribing healthcare provider.

Q: Is a rash a normal side effect of Cefalexin, or is it a sign of an allergic reaction?

A: A mild rash is a reported adverse reaction. However, regulatory information warns that a rash can also be a sign of a severe allergic reaction or hypersensitivity. If signs of a severe allergic reaction (such as hives, swelling, or difficulty breathing) occur, immediate medical attention is necessary, and the drug should generally be discontinued.

Q: What is the connection between penicillin allergy and the use of Cefalexin?

A: Cefalexin is a cephalosporin, which is chemically related to penicillin. Regulatory documents advise that it should be used with caution in patients who have a history of penicillin allergy because cross-hypersensitivity between these antibiotic classes has been documented.

Q: How long after stopping Cefalexin can side effects like diarrhea still occur?

A: According to official warnings, severe diarrhea associated with C. difficile infection (CDAD) can occur even up to 8 weeks (2 months) after administration has stopped. If a patient experiences severe symptoms such as watery or bloody stools, they should seek a professional medical evaluation.

Q: Can children take Cefalexin, and is the liquid form common for them?

A: Yes, the use of Cefalexin is established for pediatric patients over 1 year of age. The liquid form, known as oral suspension, is commonly available as it allows for easier administration and more precise dosage for this patient group.

Q: Can Cefalexin cause yeast infections, and why does this happen?

A: Regulatory warnings state that prolonged use of antibiotics like Cefalexin may lead to the overgrowth of non-susceptible organisms, which can include yeast or fungi. This mechanism is known as a superinfection and is why antibiotics may sometimes cause infections like oral thrush.

Q: What is the likelihood of developing C. difficile infection after taking Cefalexin?

A: Drug labeling notes that severe diarrhea, including diarrhea associated with C. difficile (CDAD), has been reported with Cefalexin. As with all antibacterial agents, Cefalexin carries a risk of altering the normal gut flora, which can lead to this infection.

Q: Can Cefalexin be safely taken during pregnancy or while breastfeeding?

A: Cefalexin is classified as Pregnancy Category B, meaning animal studies have not shown a risk to the fetus, but human data are limited. Regulatory information confirms that the drug is excreted in human breast milk. Decisions regarding its use during pregnancy or while nursing require professional medical consultation.

Q: How long does Cefalexin stay in your system after the last dose?

A: The drug is primarily and rapidly cleared from the body by the kidneys. Regulatory information indicates that measurable serum levels are detectable for up to approximately 6 hours after a dose, but the time for complete elimination can vary by individual.

Q: Does Cefalexin interact with any blood-thinning medications like Warfarin?

A: Yes, official labeling confirms that Cefalexin may interact with oral anticoagulants (blood thinners) such as Warfarin. This interaction can increase the risk of bleeding. For patients using both medications, professional medical supervision, including monitoring of clotting parameters, is advised.

Q: What is the risk of a severe allergic reaction (anaphylaxis) to Cefalexin?

A: Regulatory documents report that severe hypersensitivity reactions, including anaphylaxis, have been documented with Cefalexin use. If a severe allergic reaction occurs, immediate emergency medical attention is necessary.

Q: Are there different brand names for Cefalexin, and do they all work the same way?

A: Cefalexin is the generic name (or active ingredient), often known by brand names such as Keflex. All products that contain the same active ingredient and are approved by the regulatory agency are considered therapeutically equivalent, meaning they are expected to work the same way in the body.

Q: Can Cefalexin be used to treat viral infections like the common cold or flu?

A: No. Official labeling states that Cefalexin is an antibacterial drug that works by killing bacteria. It is not effective against infections caused by viruses, such as the common cold or flu.

Q: Can Cefalexin cause headaches, and if so, how common is it?

A: Official drug labeling lists headache as a possible adverse reaction. While reported, it is not categorized among the most common side effects like nausea and diarrhea.

Q: Is Cefalexin effective for treating tooth or gum infections/abscesses?

A: Regulatory information indicates Cefalexin is used to treat infections of the skin, bone, ear, and respiratory and urinary tracts. Dental professionals may prescribe Cefalexin for bacterial infections related to the mouth or teeth, though this specific use may be based on supplemental clinical guidance.

Q: What should I watch for in a child taking Cefalexin that might signal a problem?

A: Parents should monitor for the same serious adverse reactions seen in adults. This includes signs of an allergic reaction (e.g., severe rash, swelling) or severe diarrhea. These potential reactions are considered serious and require prompt medical evaluation.

Q: How often do people experience nausea when taking Cefalexin?

A: Regulatory documents classify nausea as a common adverse reaction, meaning it is one of the most frequently reported side effects. However, official product information does not typically provide an exact frequency percentage.

Q: What should I do if I vomit shortly after taking a dose of Cefalexin?

A: Vomiting is a reported side effect of Cefalexin. If a patient vomits shortly after taking a dose, professional medical guidance should be sought regarding proper continuation of the regimen.

Q: Is Cefalexin used to prevent infections, such as before dental procedures?

A: Yes, official labeling permits the use of Cefalexin to prevent infections when clinically appropriate. It may be used for prophylactic purposes in specific at-risk patients undergoing certain medical or dental procedures.

Q: Does Cefalexin have any known impact on mood or mental clarity?

A: While direct effects on mood are not typically reported, drug warnings mention potential neurotoxicity, which is a toxic effect on the nervous system. This includes the rare risk of seizures in susceptible patients, which may impact mental status and clarity.

Q: Does Cefalexin ever need to be taken more than three times a day?

A: Yes. Standard dosing regimens often include taking Cefalexin every 6 hours, which results in four doses per day. For more severe infections, the total daily dose is divided into multiple doses as prescribed by a healthcare professional.

Q: Why are some Cefalexin capsules or tablets different colors or shapes?

A: Cefalexin is manufactured by various companies, and their products (capsules, tablets, or liquid) contain different inactive ingredients (excipients). These differences in fillers and coatings are what account for the variations in color, shape, and size of the pills.

Q: Is it normal to feel a bit dizzy or tired while on Cefalexin?

A: Official regulatory documents list dizziness and fatigue as possible adverse reactions. If a patient experiences these effects, caution is generally recommended when engaging in tasks requiring mental alertness.

How should Cefalexin be stored and disposed of?

How to Store and Dispose of Cefalexin?

The official storage and disposal requirements for Cefalexin are governed by product labeling to ensure stability and safety.

Official Storage Requirements

Dosage Form Required Storage Condition Stability Constraint
Capsules/Tablets Controlled Room Temperature (20 C to 25 C). Protect from moisture. Store in original, tightly closed container.
Oral Suspension (Reconstituted) Refrigerated (2 C to 8 C). Do not freeze. Must be discarded after 14 days.

All forms must be stored out of the sight and reach of children.

Disposal Instructions

Regulatory guidelines advise against flushing Cefalexin down the toilet or pouring it into a drain. Unused or expired medication should be disposed of through an official drug take-back program or by following specific household trash methods (mixing with unpalatable substances in a sealed bag).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cefalexin found in:

A-Z Index: